UB Paderborn / Katalog / Suche / in CDI

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Annals of oncology, 2019-04, Vol.30, p.ii77-ii77

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Annals of oncology, 2018-12, Vol.29, p.x43-x43

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Link zum Volltext

Verfügbarkeit prüfen

583 TUMOR RESPONSE IN A PHASE 2 STUDY OF FIRST-LINE BRIVANIB IN HEPATOCELLULAR CARCINOMA (HCC): COMPARISON OF MODIFIED WHO AND MODIFIED RECIST CRITERIA

Journal of hepatology, 2010, Vol.52, p.S230-S231

2010

Link zum Volltext

Verfügbarkeit prüfen

68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

Annals of oncology, 2020-12, Vol.31, p.S1445-S1445

2020

Link zum Volltext

Verfügbarkeit prüfen

P.3.c.075 A 46-week evaluation of aripiprazole in combination with lithium/valproate in bipolar mania (CN138–134)

European neuropsychopharmacology, 2008, Vol.18, p.S447-S447

2008

Link zum Volltext

Verfügbarkeit prüfen

PW01-36 - The long-term safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar I patients partially non-responsive to mood stabilisers

European psychiatry, 2010, Vol.25 (S1), p.1455-1455, Article 25-E1438

2010

Link zum Volltext

Verfügbarkeit prüfen

749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032

Annals of oncology, 2020-09, Vol.31, p.S582-S583

2020

Link zum Volltext

Verfügbarkeit prüfen

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.e42-e42

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Annals of oncology, 2016-10, Vol.27, p.vi350-vi350

2016

Link zum Volltext

Verfügbarkeit prüfen

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

Annals of oncology, 2016-10, Vol.27, p.vi350-vi350

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-12, Vol.90 (5), p.1266-1267

2014

Link zum Volltext

Verfügbarkeit prüfen

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

Annals of oncology, 2012-09, Vol.23, p.ix319

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4096-4096

2010

Link zum Volltext

Verfügbarkeit prüfen

Evidence for a neuroprotective effect of pyrid-3-yl-sulphonyl-urea in photochemically induced focal ischaemia in rats: magnetic resonance imaging evaluation

Journal of pharmacy and pharmacology, 1999-08, Vol.51 (8), p.967-970

1999

Link zum Volltext

Verfügbarkeit prüfen

Exchange interactions and magneto-crystalline anisotropy in RFe12−xMx and parent interstitial compounds

Journal of alloys and compounds, 2004-11, Vol.383 (1-2), p.166-172

2004

Link zum Volltext

Verfügbarkeit prüfen

LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Annals of oncology, 2018-12, Vol.29 (suppl_10)

2018

Link zum Volltext

Verfügbarkeit prüfen

Non Invasive Quantification of Manganese Deposits in the Rat Brain by Local Measurement of NMR Proton T1 Relaxation Times

Neurotoxicology (Park Forest South), 2001-06, Vol.22 (3), p.387-392

2001

Link zum Volltext

Verfügbarkeit prüfen

Magnetic characteristics of Er(Mn 12− xFe x) compounds ( x=7, 9) determined by X-ray magnetic circular dichroism

Journal of alloys and compounds, 2001-04, Vol.317, p.470-474

2001

Link zum Volltext

Verfügbarkeit prüfen

Magnetic characteristics of Er(Mn sub 12-x Fe sub x ) compounds (x=7, 9) determined by X-ray magnetic circular dichroism

Journal of alloys and compounds, 2000-04, Vol.317-318, p.470-474

2000

Link zum Volltext

Verfügbarkeit prüfen

Non Invasive Quantification of Manganese Deposits in the Rat Brain by Local Measurement of NMR Proton T sub(1) Relaxation Times

Neurotoxicology (Park Forest South), 2001-06, Vol.22 (3), p.387-392

2001

Link zum Volltext

Verfügbarkeit prüfen

Two Theoretical Analyses of the Output Signal from an Eddy Current Sensor

Review of scientific instruments, 1971-04, Vol.42 (4), p.458-461

Baudelet, C.

1971

Link zum Volltext

Verfügbarkeit prüfen

Epsilon iron as a spin-smectic state

Proceedings of the National Academy of Sciences - PNAS, 2019-10, Vol.116 (41), p.20280-20285

2019

Link zum Volltext

Verfügbarkeit prüfen

Revisiting the Phase Transition of Magnetite under Pressure

Journal of physical chemistry. C, 2019-08, Vol.123 (34), p.21114-21119

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

583 TUMOR RESPONSE IN A PHASE 2 STUDY OF FIRST-LINE BRIVANIB IN HEPATOCELLULAR CARCINOMA (HCC): COMPARISON OF MODIFIED WHO AND MODIFIED RECIST CRITERIA

68P Evaluation of flat dosing for nivolumab (NIVO) + ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

P.3.c.075 A 46-week evaluation of aripiprazole in combination with lithium/valproate in bipolar mania (CN138–134)

PW01-36 - The long-term safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar I patients partially non-responsive to mood stabilisers

749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT)

Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data

Evidence for a neuroprotective effect of pyrid-3-yl-sulphonyl-urea in photochemically induced focal ischaemia in rats: magnetic resonance imaging evaluation

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Exchange interactions and magneto-crystalline anisotropy in RFe12−xMx and parent interstitial compounds

LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Non Invasive Quantification of Manganese Deposits in the Rat Brain by Local Measurement of NMR Proton T1 Relaxation Times

Magnetic characteristics of Er(Mn 12− xFe x) compounds ( x=7, 9) determined by X-ray magnetic circular dichroism

Magnetic characteristics of Er(Mn sub 12-x Fe sub x ) compounds (x=7, 9) determined by X-ray magnetic circular dichroism

Non Invasive Quantification of Manganese Deposits in the Rat Brain by Local Measurement of NMR Proton T sub(1) Relaxation Times

Two Theoretical Analyses of the Output Signal from an Eddy Current Sensor

Epsilon iron as a spin-smectic state

Revisiting the Phase Transition of Magnetite under Pressure

Aktive Filter

Suchergebnisse filtern